View on market: Volatility Prevails, Market is searching for better value
The stock rally driven by the exuberance surrounding artificial intelligence is widening beyond the tech industry, defying naysayers and raising concern about an overbought market. Mounting bets that the Federal Reserve will end its tightening cycle sooner rather than later to prevent a recession added fuel to the equity advance, with the S&P 500 topping 4,400 and rising for a sixth straight day. The Dow Jones Industrial Average extended its advance from a September low to almost 20%, while the Nasdaq 100 closed at its highest since March 2022. Meanwhile, Brent crude was trading around $75 a barrel and West Texas Intermediate rose to $70. The yield on the 10-year U.S. bond was trading at 3.72%, whereas Bitcoin was around 25,000-level. At 05:23 a.m., the Singapore-traded SGX Nifty, an early indicator of the Nifty 50 Index’s performance in India was up 0.42% at 18,838.5.
Economic Calendar:
- USD : Building Permits (May) on 20th June, 2023
- USD : Initial Jobless Claims on 22nd June, 2023
- INR : Bank Loan Growth on 16th June, 2023
- INR : FX Reserves, USD on 23rd June, 2023
Brokerage Radar:
NOMURA ON ITC: Buy Rating; Target Rs 485; Cigarettes Biz, Volume Trajectory Remains Strong; Growth Over Coming Quarters Will Optically Come Down To Mid-to-high Single Digits; FMCG Biz, Co Endeavours To Outpace Industry Growth Over The Medium Term; Hotels Biz, Divestment Is On Cards, Evaluating Alternatives To Ensure Cost & Tax Efficiency
MS ON INDIGO: OW, TP Rs 3126; All Key Earnings Drivers Are Moving Favorably
Near-term Profit Per Seat Could Hit A Cyclical High; On Normalised Earnings & Median Multiple, See 33% Upside; Stock Trades At FY25 EV/EBITDA Of 6.6x Vs Pre-COVID Median Of 8.5x
JEFFERIES ON PIRAMAL PHARMA: Buy Rating; Target Rs 115; Started The Year On A Strong Note With Healthy Order Book In CDMO Division; See Rise In FTE Discovery Demand & Supply Normalisation In Complex Hospital Generics; Deep Dive Into NCE Contracts Gives Confidence In Significant Margin Expansion In FY24; Upside Risk To Our Est Could Come From Strong Demand In CHG Products
International Markets
U.S & Europe:
Particulars | 15th June | Chg. | Chg.(%) |
Nasdaq | 13782.82 | 156.34 | 1.15 |
Dow | 34408.06 | 428.73 | 1.26 |
FTSE | 7628.26 | 25.52 | 0.33 |
CAC | 7290.91 | -37.62 | -0.52 |
DAX | 16290.12 | -20.67 | -0.13 |
Dow Fut.* | 34362.20 | -45.90 | -0.13 |
Asian markets
Particulars | 16th June | Chg. | Chg.(%) |
SGX Nifty | 18804.00 | 44.00 | 0.23 |
Nikkei | 33305.96 | -179.53 | -0.54 |
Straits Times | 3261.81 | 18.96 | 0.58 |
Hang Seng | 19929.81 | 100.89 | 0.51 |
Shanghai | 3262.00 | 9.02 | 0.28 |
ADR Watch:
Particulars | 15th June | Chg. | Chg.(%) |
Dr. Reddy | 59.41 | 1.70 | 2.95 |
HDFC Bank | 64.60 | 0.24 | 0.37 |
ICICI Bank | 22.87 | -0.08 | -0.35 |
Infosys | 15.62 | 0.06 | 0.39 |
Wipro | 4.70 | -0.01 | -0.21 |
Commodities & Currency
Particulars | Current Price | Chg.(%) |
USD/INR | 81.98 | 0.09 |
Brent | 75.55 | -0.16 |
Gold | 1968.70 | -0.10 |
Silver | 23.995 | 0.20 |
FIIs & DIIs:
Particulars | 15th June | 14th June |
FIIs | 3085.51 | 1714.72 |
DIIs | -297.88 | -654.77 |
News Update:
Tech Mahindra: Company appointed Mohit Joshi as managing director and chief executive officer of the company with effect from Dec. 20, 2023 to June 19,2028. Current MD and CEO CP Gurnani will retire on Dec. 19, 2023.
Titagarh Wagons, Ramakrishna Forgings: Titagarh Wagons, Ramakrishna Forgings won Rs 12,226.5 crore contract to manufacture and supply 15,40,000 forged wheels over a span of 20 years for Indian railways. As per the contract, 40,000 forged wheels will be delivered during the first year, 60,000 wheels in the second year and 80,000 wheels every subsequent year thereafter.
TVS Motor Company: The automaker sold its entire stake of 11.12 crore equity shares, or 43.54% stake, held in associate company Emerald Haven Realty for Rs 166.83 crore to TVS Holdings, a promoter group company.
Bharat Heavy Electricals, Eicher Motors: BHEL, Volvo Eicher Commercial Vehicles inked a memorandum of understanding to jointly develop and deploy Type-IV hydrogen, CNG cylinders in commercial vehicles segment.
Torrent Pharma: U.S. FDA has issued an Establishment Inspection Report after inspecting the drugmaker’s oral-oncology manufacturing facility at Bileshwarpura in Gujarat.
Natco Pharma: U.S. FDA has issued an Establishment Inspection Report after inspecting Natco’s drug formulations manufacturing facility at Visakhapatnam in Andhra Pradesh from Jan. 30 to Feb. 3.
Power Finance Corporation: Company’s wholly owned subsidiary PFC Consulting has been nominated as Bid Process Coordinator for development of Independent Transmission Projects by Power Ministry. The company will take up the special purpose vehicle route to execute the tariff based competitive bidding process.
NLC India: Company has incorporated wholly-owned subsidiary, NLC India Renewables, to take over the existing renewable assets of the company.
Source: Moneycontrol, Bloomberg Quint, Investing
Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014
Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Kiran Tahlani, Elite Wealth Limited, kirantahlani@elitestock.com
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or e-mailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
- Reports
- a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
- Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL
Provided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and (b) of clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant banking or brokerage services transactions of the subject company.
(4) EWL or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWL has never been engaged in market making activity for the subject company;
(6) EWL shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulations.